US2012136145A1PendingUtilityA1
Compositions and Methods for Inhibiting Expression of Eg5 Gene
Est. expiryMar 31, 2026(expired)· nominal 20-yr term from priority
C12N 2310/3233C12N 2310/111C12N 2310/321C12N 2310/14C12N 2310/315C12N 15/1137C12N 2310/3515C12N 2330/30C12N 2310/322C12N 2310/314A61P 43/00C12N 15/1138A61P 35/00C07H 21/02C12N 15/113A61K 48/00
60
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Eg5 gene (Eg5 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the Eg5 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Eg5 expression and the expression of the Eg5 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Eg5 gene in a cell.
Claims
exact text as granted — not AI-modified1 - 31 . (canceled)
32 . A double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a human kinesin family member 11 (Eg5) gene in a cell, wherein said dsRNA comprises a sense strand comprising a first sequence and an antisense strand comprising a second sequence complementary to at least 15 contiguous nucleotides of SEQ ID NO:1311, wherein said first sequence is complementary to said second sequence and wherein said dsRNA is 19 base pairs in length.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.